Remote patient monitoring to simplify risk evaluation and mitigation strategy (REMS) protocols
While cell therapies, including CAR-T therapy, are incredibly effective at treating blood cancers like leukemia, patients often suffer serious side effects. Up to 93% of patients develop cytokine release syndrome (CRS), and 33% of patients experience immune effector cell-associated neurotoxicity syndrome (ICANS). Early intervention is key for these complications, and digital solutions can make all the difference.
In this white paper, we explore the role connected wearables and support apps can play in helping patients, caregivers, and providers detect and treat CRS and ICANS in a timely manner. These digital solutions provide many valuable services, including:
- Educational content
- Seamless data capture
- Messaging tools to connect a patient with their care team
- Appointment reminders
Read the white paper today to learn more about how connected wearables and support apps can aid in early detection of CRS and ICANS in patients receiving cell therapy.
Biopharma and R&D